Overview

• Relay Therapeutics Q3 net loss was $74.15 mln, slightly missing analyst expectations

• Operating expenses decreased due to strategic cost-cutting measures

• Company advances RLY-2608 trials and appoints two new board members

• Approximately $596 million in cash, cash equivalents and investments at end of Q3 2025

Outlook

• Company expects cash reserves to fund operations into 2029

Result Drivers

• CLINICAL TRIAL EXECUTION - Continued advancement of RLY-2608 trials in breast cancer and vascular malformations contributed to increased costs

• COST MANAGEMENT - Strategic choices to streamline research and decrease stock compensation expenses reduced operating costs

• R&D EXPENSES: Research and development expenses were $68.3 million for the third quarter of 2025, as compared to $76.6 million for the third quarter of 2024

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Relay Therapeutics Inc is $14.50, about 54.8% above its November 5 closing price of $6.55

Press Release: ID:nGNX4BzqLv

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)